Welcome to the e-CCO Library Archive!
R. Dudkowiak1, P. Petryszyn1, L. Paradowski1, 1Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland
Prevalence of impaired muscle strength in an IBD outpatient cohort.
C. Spooren*, M. Pierik, T. van den Heuvel, E. de Koning, Z. van Mechelen, A. Masclee, D. Jonkers
Maastricht University Medical Center+, Internal Medicine - Division Gastroenterology-Hepatology, Maastricht, Netherlands
Predictive factors of early infliximab infusion reactions in inflammatory bowel disease
C. Duron1, A. Buisson1, B. Pereira2, G. Bommelaer1, 1University Hospital Estaing, Gastroenterology department, Clermont-Ferrand, France, 2DRCI, Biostatistics Unit, Clermont-Ferrand, France
M. Protic1, P. Frei2, Z. Radojicic3, A. Schoepfer4, P. Juillerat5, C. Mottet6, G. Rogler7, C. Beglinger8, F. Seibold1, 1Spital Netz Bern, Gastroenterology, Bern, Switzerland, 2See Spital, Gastroenterology, Horgen, Switzerland, 3Faculty of Organizational Sciences, Statistcs, Belgrade, Serbia, 4Centre hospitalier universitaire Vaudois, Gastroenterology, Lausanne, Switzerland, 5University Hospital Bern Inselspital, Gastroenterology, Bern, Switzerland, 6Hospital Neuchâtel, Gastroenterology, Neuchâtel, Switzerland, 7University Hospital Zürich, Gastroenterology, Zürich, Switzerland, 8University Hospital Basel, Gastroenterology, Basel, Switzerland
Overweight impairs short-term outcomes of laparoscopic IBD surgery. A comparative analysis of 639 consecutive patients.
L. Maggiori*1, M. Couturier1, X. Tréton2, Y. Bouhnik2, Y. Panis1
1Beaujon Hospital, Colorectal Surgery, Clichy, France, 2Beaujon Hospital, Gastroenterology, Clichy, France
Predictive factors of response to prolonged intravenous corticosteroids in patients with acute severe ulcerative colitis
D.J. Lee, M.E. Song, S.J. Park, S.P. Hong, T.I. Kim, W.H. Kim, J.H. Cheon, Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea
S. Sharma1, R. Pradhan1, R. Thakkar1, A. Robinson1, J. Hyams2, J. Rosh3, F.M. Ruemmele4, W. Awni1, 1Abbott Laboratories, United States, 2Connecticut Children's Med Ctr, United States, 3NJ Medical School, United States, 4Hôpital Necker-Enfants Malades, France
Golimumab maintenance treatment and fecal calprotectin predict continuous clinical response in ulcerative colitis.
W. Reinisch*1, 2, J.-F. Colombel3, W. Sandborn4, B. Feagan5, C. Marano6, R. Strauss6, S. Huyck7, R. Yao7, P. Rutgeerts8, H. Zhang9, F. Cornillie10
1McMaster University, Department of Internal Medicine, Hamilton, Canada, 2Medical University, Department of Internal Medicine III, Vienna, Austria, 3Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States, 4University of California San Diego, Division of Gastroenterology, La Jolla, United States, 5University of Western Ontario, Robarts Research Institute, London, Canada, 6Janssen R&D, LLC, Clinical Development Immunology, Spring House, United States, 7Merck & Co., Inc., Department of Statistics, Merck Research Laboratories, Whitehouse Station, United States, 8University Hospital Gasthuisberg, Division of Gastroenterology, Leuven, Belgium, 9Merck & Co., Inc., Clinical Biostatistics, Biometrics and Reporting, Whitehouse Station, United States, 10MSD International, Immunology Medical Affairs, Luzern, Switzerland
Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn's disease
M. Rosario1, N. Dirks2, M. Gastonguay2, I. Fox1, A. Milton1, 1Takeda Pharmaceuticals International Company, Clinical Pharmacology, Cambridge, United States, 2Metrum Research Group LLC, Biotechnology, Tariffville, United States
R. Pradhan1, S. Sharma1, R. Thakkar1, A. Robinson1, J. Hyams2, J. Rosh3, F.M. Ruemmele4, W. Awni1, 1Abbott Laboratories, United States, 2Connecticut Children's Med Ctr, United States, 3NJ Medical School, United States, 4Hôpital Necker-Enfants Malades, France
Azathioprine and 6-Mercaptopurine use in the Swiss IBD cohort: adverse effects, causes of discontinuation and risk of "flares" according to 6-TG levels
D. Lavrek*1, N. Fournier1, V. Pittet1, D. Müller2, C. Mottet1, 3, 4
1Lausanne University Hospital, Institute of Social & Preventive Medicine (IUMSP), Lausanne, Switzerland, 2Zürich University Hospital, Institute of Clinical Chemistry, Zürich, Switzerland, 3Lausanne University Hospital, Division of Gastroenterology & Hepatology, Lausanne, Switzerland, 4Hôpital Neuchâtelois, Division of Gastroenterology, Neuchâtel, Switzerland
Pharmacokinetics of laquinimod in patients with active moderate to severe Crohn's disease
G. D'Haens1, W.J. Sandborn2, P. Rutgeerts3, J.F. Colombel4, D. Mimrod5, O. Spiegelstein5, K. Brown6, B. Feagan7, 1University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands, 2University of California, UCSD Inflammatory Bowel Disease Center, San Diego CA, United States, 3Catholic University of Leuven, Department of Internal Medicine and Endoscopy, Leuven, Belgium, 4Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, 5Teva Pharmaceuticals, Phase-1 & Clinical Pharmacology Research and Development, Netanya, Israel, 6Teva Pharmaceuticals, Clinical Development Research and Development, Frazer, United States, 7University of Western Ontario, Robarts Clinical Trials Robarts Research Institute, Ontario, Canada
I. Gubonina1, A. Pershko1, A. Dragun2, 1Military Medical Academy, 2nd Therapy Dpt, St-Petersburg, Russian Federation, 2International Medical Centre “Sogaz”, Out-patient department, St-Petersburg, Russian Federation
Durability of the anti-HBs titers after vaccination against Hepatitis B virus (HBV) in patients with Inflammatory Bowel Disease (IBD)
M. Chaparro*1, J. Gordillo2, E. Domènech3, M. Esteve4, M. Barreiro de-Acosta5, A. Villoria6, E. Iglesias-Flores7, M. Blasi2, J.E. Naves8, O. Benítez9, X. Calvet10, V. García-Sánchez7, J.R. Villagrasa11, A.C. Marín1, M. Ramas1, I. Moreno12, J.P. Gisbert1
1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Santa Creu i Sant Pau, Gastroenterology Unit, Barcelona, Spain, 3Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain, 4Hospital Universitario Mutua de Terrassa, Gastroenterology Unit, Terrassa, Spain, 5Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 6Hospital de Sabadell and CIBERehd, Gastroenterology Unit, Sabadell, Spain, 7Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 8Hospital Universitario Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Barcelona, Spain, 9Hospital Universitario Mutua de Terrassa and CIBERehd. , Gastroenterology Unit, Terrassa, Spain, 10Hospital de Sabadell. Corporació Sanitària Universitària Parc Taulí and CIBERehd, Gastroenterology Unit, Sabadell, Spain, 11Hospital Universitario de La Princesa and IIS-IP , Preventive medicine unit, Madrid, Spain, 12Hospital Universitario de La Princesa and IIS-IP , Fundación de Investigación Biomédica, Madrid, Spain
Persistence of antibodies to infliximab for more than two months strongly predicts loss of response to infliximab in inflammatory bowel diseases
M. Leclerc1, H. Marotte2, S. Paul3, E. Del Tedesco1, P. Gonzalo4, J.M. Phelip1, L. Peyrin Biroulet5, X. Roblin1, 1University Hospital, Gastroenterology, Saint Etienne, France, 2University Hospital, Rheumatology, Saint Etienne, France, 3University Hospital, Immunology, Saint Etienne, France, 4University Hospital, Biochimy, Saint Etienne, France, 5CHU de Nancy, Gastroenterologie, Vandoeuvre-les-Nancy, France